- Agilent Technologies (A, Financial) launches the InfinityLab Pro iQ Series, a new standard in LC-mass detection.
- The series offers advanced solutions for pharmaceutical, biopharmaceutical, and environmental testing industries.
- The Pro iQ Plus system caters to high-end applications requiring ultimate sensitivity and performance.
Agilent Technologies Inc. (A), a leader in laboratory analytical instruments, has unveiled its latest advancement in liquid chromatography (LC)-mass detection with the launch of the Agilent InfinityLab Pro iQ Series. This innovative series, which includes the InfinityLab Pro iQ and the InfinityLab Pro iQ Plus, is designed to address the diverse analytical needs of modern laboratories.
With a focus on pharmaceutical, biopharmaceutical, academic, and governmental institutions, the Pro iQ Series is engineered for precision and sensitivity in detecting and analyzing essential molecules such as therapeutic small molecules, oligonucleotides, peptides, and proteins. The systems facilitate crucial applications like mass confirmation, impurity profiling, and biomolecule characterization, enhancing both basic and advanced analytical workflows.
The InfinityLab Pro iQ Plus, specifically tailored for high-end research and development environments, offers an extended mass range of m/z 2–3,000 and improved sensitivity via Agilent Jet Stream technology. This makes it particularly suitable for advanced R&D settings where enhanced analytical performance is essential.
Jennifer Gushue, Associate Vice President of LC/MS Product Marketing, emphasized the versatility of the new systems: “The Pro iQ Series opens new possibilities across a wide spectrum of application areas—from pharmaceutical development and quality control to biotherapeutics and environmental testing. These systems provide the precision, sensitivity, and intelligence needed to address future scientific challenges.”
Agilent Technologies (A, Financial) remains committed to offering cutting-edge solutions that support scientific discoveries and operational efficiency within laboratory settings. With a revenue of $6.51 billion in fiscal year 2024, Agilent continues to be a key player in analytical and clinical laboratory technologies.
